| We evaluated the safety, tolerability, pharmacokinetics, and preliminary clinical efficacy of napabucasin (480 mg/day) plus sorafenib (800 mg/day) in Japanese patients with unresectable hepatocellular carcinoma (HCC). |
| No dose-limiting toxicities occurred, and the safety profile was manageable. Four of six patients had stable disease, and two patients had stable disease lasting ≥ 12 weeks. |
| This therapeutic combination appears to be viable for the treatment of advanced HCC, with no tolerability concerns, and further clinical investigation may be warranted. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.